DPYSL5 and lung cancer: Lung cancer was the cancer most frequently associated with CRMP5 antibodies (14 patients, 58%) and peripheral neuropathy (sensory-motor neuropathy) was the most prevalent neurological diagnosis (10 patients, 42%) associated with such cancer.